Sunday, June 1, 2025

Latest

Artificial Intelligence Meets Psychedelics – The Daily Dive feat Fabio Chianelli

Today on the Daily Dive, Fabio Chianelli, CEO of PharmaTher Inc (CSE: PHRM) sits down with our host Cassandra Leah to discuss the company as well as the psychedelic space in general. Within, he discusses his outlook for the growing psychedelic renaissance as well as the direction that PharmaTher is headed in terms of research and development.

Pharmather is one of the latest firms to begin trading on the Canadian Securities Exchange, with a focus on the psychedelic space. The company works to combine artificial intelligence with research and development to develop solutions for unmet medical needs with these psychedelic compounds. The company is currently focused on the brain and nervous system, with a number of target conditions already identified.

Check out the full interview below.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

How a Single Deal Turned 2 ‘Dead’ Mines into a $2B Project | Canadian Copper PEA – Simon Quick

Silver47 x Summa Silver: Creating An Explorer With A Billion Ounce Goal

Alamos Gold Q1 Earnings: The Inside Scoop

Recommended

Silver47 x Summa Silver: Creating An Explorer With A Billion Ounce Goal

Canadian Copper: The $172M Combined Strategy PEA

Related News

Pharmather: Combining Artificial Intelligence With Psychedelics For Novel Drug Discovery

Newscope Capital, whom is currently doing business as Pharmather (CSE: PHRM) is the latest firm...

Monday, October 12, 2020, 03:47:00 PM

PharmaTher To Commence Phase 2 Clinical Study On Ketamine In Q2 2021

Pharmather Inc (CSE: PHRM) is successfully progressing on the development of its proposed phase 2...

Thursday, February 4, 2021, 08:28:04 AM

PharmaTher Acquires Exclusive Rights To Patented Ketamine Formulation

PharmaTher Inc (CSE: PHRM) has entered into an exclusive worldwide license agreement for the development...

Tuesday, January 19, 2021, 09:24:20 AM

Musk’s Ketamine Use Is Apparently In Everyone’s Best Interest

Tesla Inc (Nasdaq: TSLA) CEO Elon Musk believes that his prescribed use of ketamine is...

Tuesday, March 19, 2024, 05:12:50 PM

PharmaTher Files Patent For Use Of Ketamine In Type 2 Diabetes, Obesity

PharmaTher Holdings (CSE: PHRM) has expanded its patent portfolio. The company this morning announced the...

Tuesday, April 27, 2021, 07:54:44 AM